GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory TreatmentsMarketBeat • Monday
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision MedicineGlobeNewsWire • 11/03/26
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks Investment Research • 10/29/26
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress TranscriptSeeking Alpha • 10/27/26
GSK, Hansoh's bone cancer drug delays disease progression in late-stage China studyReuters • 10/26/26
Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?24/7 Wall Street • 10/24/26
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/21/26
GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies saysProactive Investors • 10/21/26
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)Business Wire • 10/20/26
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatmentReuters • 10/20/26